03:58 PM EDT, 09/09/2025 (MT Newswires) -- Tevogen Bio ( TVGN ) said Tuesday it guided for 5-year topline revenue of around $6.5 billion for TVGN 116 to prevent liver cancer in people with high-risk chronic Hepatitis B infections.

The risk-adjusted net present value estimate for the asset exceeds almost $325 million, according to a company statement.

Shares rose 1.3% in recent trading.

Price: 0.90, Change: +0.02, Percent Change: +1.80